Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Cited By ~ 3

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1005 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1005-1005 ◽

Cited By ~ 1

Author(s):

Guy Heinrich Maria Jerusalem ◽

Elena Kovalenko ◽

Denise A. Yardley ◽

Richard H. De Boer ◽

Sara A. Hurvitz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Epidermal Growth

Abstract OT2-1-02: A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer

10.1158/1538-7445.sabcs14-ot2-1-02 ◽

2015 ◽

Author(s):

Andre Mattar ◽

Rodrigo Goncalves ◽

Matthew J Ellis ◽

Roberto Hegg

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Premenopausal Women ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive

Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer

10.1158/0008-5472.sabcs13-ot2-6-13 ◽

2013 ◽

Author(s):

HS Rugo ◽

O Tredan ◽

J Ro ◽

SM Morales ◽

A Musolina ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Abstract P2-08-03: Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

10.1158/1538-7445.sabcs16-p2-08-03 ◽

2017 ◽

Author(s):

AM DeMichele ◽

AS Clark ◽

R Holmes ◽

M Volpe ◽

C Medrano ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Jak Inhibitor ◽

Phase 2 ◽

Inflammatory Pathways ◽

Phase 2 Trial ◽

Positive Breast Cancer

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Cancer ◽

10.1002/cncr.30143 ◽

2016 ◽

Vol 122 (19) ◽

pp. 3032-3040 ◽

Cited By ~ 11

Author(s):

Florence Lerebours ◽

Sofia Rivera ◽

Marie-Ange Mouret-Reynier ◽

Severine Alran ◽

Laurence Venat-Bouvet ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Postmenopausal Estrogen ◽

Epidermal Growth ◽

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

Cancer ◽

10.1002/cncr.22789 ◽

2007 ◽

Vol 110 (2) ◽

pp. 244-254 ◽

Cited By ~ 197

Author(s):

Vladimir F. Semiglazov ◽

Vladislav V. Semiglazov ◽

Garik A. Dashyan ◽

Elena K. Ziltsova ◽

Vadim G. Ivanov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Randomized Trial ◽

Endocrine Therapy ◽

Phase 2 ◽

Primary Endocrine Therapy ◽

Positive Breast Cancer

Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)

10.1158/1538-7445.sabcs20-pd1-01 ◽

2021 ◽

Author(s):

José Á García-Saenz ◽

Noelia Martínez Jáñez ◽

Miguel Martin ◽

Ainhara Lahuerta Martínez ◽

Santiago González-Santiago ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Aromatase Inhibitor Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.

10.1158/0008-5472.sabcs-16 ◽

2009 ◽

Cited By ~ 3

Author(s):

MJ Ellis ◽

F Dehdahti ◽

A Kommareddy ◽

S Jamalabadi-Majidi ◽

R Crowder ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Low Dose ◽

High Dose ◽

Phase 2 ◽

Phase 2 Trial ◽